• Explore /
  • Poster
  • / APACT: Phase III randomized trial of adjuvant treatment with <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).

APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).

Abstract Poster

Authors

null

Margaret A. Tempero

University of California, San Francisco, San Francisco, CA

Margaret A. Tempero , Dana Backlund Cardin , David Goldstein , Eileen Mary O'Reilly , Philip Agop Philip , Hanno Riess , Teresa Macarulla , Lotus Yung , Mingyu Li , Brian D. Lu , Andrew Biankin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01964430

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr TPS473)

DOI

10.1200/jco.2016.34.4_suppl.tps473

Abstract #

TPS473

Poster Bd #

O1

Abstract Disclosures

Similar Posters

First Author: Akihiro Ohba

First Author: Michele Reni

Poster

2015 Gastrointestinal Cancers Symposium

A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.

A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.

First Author: Andrew Barbour

First Author: David Goldstein